Tumor immune profiling-based neoadjuvant immunotherapy for locally advanced melanoma
Source: MDLinx, June 2020
Given that the frequency of “exhausted” or checkpoint-positive (PD-1+CTLA-4<sup>+</sup>) cytotoxic lymphocytes (Tex) in the tumor microenvironment is correlated with response to anti-PD-1 therapy in metastatic melanoma, researchers ascertained if pretreatment Tex cells in locally advanced melanoma anticipated response to neoadjuvant anti-PD-1 blockade. Pretreatment tumor samples from 17 individuals with locally advanced melanoma had flow cytometric analysis of pretreatment Tex and regulatory T cell frequency. Patients who met the neoadjuvant checkpoint blockade criteria were treated either PD-1 monotherapy or PD-1/CTLA-4 combination therapy.
READ THE ORIGINAL FULL ARTICLE